Veracyte (VCYT) Research & Development (2012 - 2026)

Veracyte has disclosed Research & Development across 15 years of filings, most recently posting $27.1 million for Q1 2026.

• Research & Development for Q1 2026 came in at $27.1 million, up 52.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $80.2 million (up 12.87% YoY), and the FY2025 annual result was $70.8 million, up 2.19% from the prior year.
• Research & Development came in at $27.1 million for Q1 2026 at Veracyte, up from $20.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $27.1 million in Q1 2026 to a low of $9.2 million in Q1 2022.
• The 5-year median for Research & Development is $16.0 million (2025), against an average of $15.6 million.
• Across the five-year window, Research & Development soared 71.78% in 2022 and slipped 9.06% in 2025, its largest moves.
• Veracyte's Research & Development stood at $11.3 million in 2022, then jumped by 65.44% to $18.7 million in 2023, then grew by 3.3% to $19.3 million in 2024, then climbed by 8.08% to $20.8 million in 2025, then increased by 29.97% to $27.1 million in 2026.
• The last three Research & Development figures came in at $27.1 million (Q1 2026), $20.8 million (Q4 2025), and $16.0 million (Q3 2025), per Business Quant data.